Whitepaper: Six Changes that Pharmaceutical Companies Should Consider in Response to COVID-19
[Fill out the form below to access the whitepaper]
In the wake of the global pandemic of COVID-19, also known and SARS-COV-2, regulators, health authorities, and lawmakers across the globe have rushed to implement countermeasures and develop best practices to curtail the spread.
They have also taken note of how the spread of the disease, and the mitigation efforts put in place, will impact clinical trials across the globe. To this end, several regulatory agencies have issued guidance documents to assist sponsors in making decisions for managing clinical studies at all stages.
Experts at MMS have reviewed these guidance documents and taken into account the current state of clinical research globally to ensure our services align with these new challenges, whether those sponsors be virtual or large firms with treatments for common illnesses or rare conditions. What has been identified are key areas of change faced by the industry.
Assessing risk in the current environment
Adjusting to the COVID-19 pandemic is proving to be difficult and is likely to take every sponsor longer than they would like, especially as…